BREAST-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2261187, encodeId=ca36226118e75, content=第一次投稿3天就拒了，理由是英语不行。隔了几天送公司润色以后重投，2周了还在with editor，什么情况呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f03a5212947, createdName=147637f2m97(暂无昵称), createdTime=Sat Apr 19 21:34:33 CST 2025, time=2025-04-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2121386, encodeId=d1be212138615, content=偏重的研究方向：乳腺癌 经验分享：3月15号投稿，with editor一个星期了还没变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=693f2340343, createdName=1228cbd9m21暂无昵称, createdTime=Thu Mar 23 18:13:28 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248480, encodeId=264a124848078, content=偏重的研究方向：乳腺癌;人工智能;病理组学 经验分享：九月二号投稿，九月五号under review，九月八号两个审稿人审稿，目前还没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:24:24 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248479, encodeId=dff212484e9fb, content=审稿速度:2.0 偏重的研究方向：乳腺癌;人工智能;病理组学 经验分享：九月二号投稿，九月五号直接跳过了with editor直接进入under review，九月八号两个审稿人接受审稿，目前任然这种状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:13:04 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236987, encodeId=0c74123698e5b, content=偏重的研究方向：临床试验 经验分享：2022-8-5投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3998253073, createdName=ms8000002072646838, createdTime=Sat Aug 06 20:56:00 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215107, encodeId=e8f4121510ec2, content=投稿命中率:50.0 经验分享：刚才写错了，应该是with editor要整整28天，然后才决定是送审还是直接拒稿。一审时间用21天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:29:02 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215106, encodeId=20aa12151064f, content=投稿命中率:50.0 经验分享：一审时间28天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:25:48 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947694, encodeId=42fb94e6942d, content=Mar 11投稿 Mar 12 with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Fri Mar 12 16:08:06 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519810, encodeId=6e58519810e6, content=投稿命中率:25.0 经验分享：meta分析，八天到编辑手里，两天后被拒，说不适合他们的读者群体。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=428, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160302/IMG56D6C38ABA3084997.jpg, createdBy=62fd1694347, createdName=旭哥, createdTime=Thu Mar 03 09:04:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800825, encodeId=a45a800825de, content=请问该期刊With Editor一般多久，该状态主要干什么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Jul 01 21:24:06 CST 2020, time=2020-07-01, status=1, ipAttribution=)]

2025-04-19 147637f2m97(暂无昵称) 来自浙江省

第一次投稿3天就拒了，理由是英语不行。隔了几天送公司润色以后重投，2周了还在with editor，什么情况呀？

8 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2261187, encodeId=ca36226118e75, content=第一次投稿3天就拒了，理由是英语不行。隔了几天送公司润色以后重投，2周了还在with editor，什么情况呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f03a5212947, createdName=147637f2m97(暂无昵称), createdTime=Sat Apr 19 21:34:33 CST 2025, time=2025-04-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2121386, encodeId=d1be212138615, content=偏重的研究方向：乳腺癌 经验分享：3月15号投稿，with editor一个星期了还没变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=693f2340343, createdName=1228cbd9m21暂无昵称, createdTime=Thu Mar 23 18:13:28 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248480, encodeId=264a124848078, content=偏重的研究方向：乳腺癌;人工智能;病理组学 经验分享：九月二号投稿，九月五号under review，九月八号两个审稿人审稿，目前还没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:24:24 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248479, encodeId=dff212484e9fb, content=审稿速度:2.0 偏重的研究方向：乳腺癌;人工智能;病理组学 经验分享：九月二号投稿，九月五号直接跳过了with editor直接进入under review，九月八号两个审稿人接受审稿，目前任然这种状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:13:04 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236987, encodeId=0c74123698e5b, content=偏重的研究方向：临床试验 经验分享：2022-8-5投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3998253073, createdName=ms8000002072646838, createdTime=Sat Aug 06 20:56:00 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215107, encodeId=e8f4121510ec2, content=投稿命中率:50.0 经验分享：刚才写错了，应该是with editor要整整28天，然后才决定是送审还是直接拒稿。一审时间用21天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:29:02 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215106, encodeId=20aa12151064f, content=投稿命中率:50.0 经验分享：一审时间28天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:25:48 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947694, encodeId=42fb94e6942d, content=Mar 11投稿 Mar 12 with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Fri Mar 12 16:08:06 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519810, encodeId=6e58519810e6, content=投稿命中率:25.0 经验分享：meta分析，八天到编辑手里，两天后被拒，说不适合他们的读者群体。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=428, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160302/IMG56D6C38ABA3084997.jpg, createdBy=62fd1694347, createdName=旭哥, createdTime=Thu Mar 03 09:04:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800825, encodeId=a45a800825de, content=请问该期刊With Editor一般多久，该状态主要干什么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Jul 01 21:24:06 CST 2020, time=2020-07-01, status=1, ipAttribution=)]

2023-03-23 1228cbd9m21暂无昵称

偏重的研究方向：乳腺癌
经验分享：3月15号投稿，with editor一个星期了还没变化

101 4 举报

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2261187, encodeId=ca36226118e75, content=第一次投稿3天就拒了，理由是英语不行。隔了几天送公司润色以后重投，2周了还在with editor，什么情况呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f03a5212947, createdName=147637f2m97(暂无昵称), createdTime=Sat Apr 19 21:34:33 CST 2025, time=2025-04-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2121386, encodeId=d1be212138615, content=偏重的研究方向：乳腺癌 经验分享：3月15号投稿，with editor一个星期了还没变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=693f2340343, createdName=1228cbd9m21暂无昵称, createdTime=Thu Mar 23 18:13:28 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248480, encodeId=264a124848078, content=偏重的研究方向：乳腺癌;人工智能;病理组学 经验分享：九月二号投稿，九月五号under review，九月八号两个审稿人审稿，目前还没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:24:24 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248479, encodeId=dff212484e9fb, content=审稿速度:2.0 偏重的研究方向：乳腺癌;人工智能;病理组学 经验分享：九月二号投稿，九月五号直接跳过了with editor直接进入under review，九月八号两个审稿人接受审稿，目前任然这种状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:13:04 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236987, encodeId=0c74123698e5b, content=偏重的研究方向：临床试验 经验分享：2022-8-5投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3998253073, createdName=ms8000002072646838, createdTime=Sat Aug 06 20:56:00 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215107, encodeId=e8f4121510ec2, content=投稿命中率:50.0 经验分享：刚才写错了，应该是with editor要整整28天，然后才决定是送审还是直接拒稿。一审时间用21天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:29:02 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215106, encodeId=20aa12151064f, content=投稿命中率:50.0 经验分享：一审时间28天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:25:48 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947694, encodeId=42fb94e6942d, content=Mar 11投稿 Mar 12 with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Fri Mar 12 16:08:06 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519810, encodeId=6e58519810e6, content=投稿命中率:25.0 经验分享：meta分析，八天到编辑手里，两天后被拒，说不适合他们的读者群体。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=428, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160302/IMG56D6C38ABA3084997.jpg, createdBy=62fd1694347, createdName=旭哥, createdTime=Thu Mar 03 09:04:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800825, encodeId=a45a800825de, content=请问该期刊With Editor一般多久，该状态主要干什么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Jul 01 21:24:06 CST 2020, time=2020-07-01, status=1, ipAttribution=)]

2022-09-12 ms3000000995770335

偏重的研究方向：乳腺癌;人工智能;病理组学
经验分享：九月二号投稿，九月五号under review，九月八号两个审稿人审稿，目前还没有变化

170 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2261187, encodeId=ca36226118e75, content=第一次投稿3天就拒了，理由是英语不行。隔了几天送公司润色以后重投，2周了还在with editor，什么情况呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f03a5212947, createdName=147637f2m97(暂无昵称), createdTime=Sat Apr 19 21:34:33 CST 2025, time=2025-04-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2121386, encodeId=d1be212138615, content=偏重的研究方向：乳腺癌 经验分享：3月15号投稿，with editor一个星期了还没变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=693f2340343, createdName=1228cbd9m21暂无昵称, createdTime=Thu Mar 23 18:13:28 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248480, encodeId=264a124848078, content=偏重的研究方向：乳腺癌;人工智能;病理组学 经验分享：九月二号投稿，九月五号under review，九月八号两个审稿人审稿，目前还没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:24:24 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248479, encodeId=dff212484e9fb, content=审稿速度:2.0 偏重的研究方向：乳腺癌;人工智能;病理组学 经验分享：九月二号投稿，九月五号直接跳过了with editor直接进入under review，九月八号两个审稿人接受审稿，目前任然这种状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:13:04 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236987, encodeId=0c74123698e5b, content=偏重的研究方向：临床试验 经验分享：2022-8-5投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3998253073, createdName=ms8000002072646838, createdTime=Sat Aug 06 20:56:00 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215107, encodeId=e8f4121510ec2, content=投稿命中率:50.0 经验分享：刚才写错了，应该是with editor要整整28天，然后才决定是送审还是直接拒稿。一审时间用21天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:29:02 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215106, encodeId=20aa12151064f, content=投稿命中率:50.0 经验分享：一审时间28天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:25:48 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947694, encodeId=42fb94e6942d, content=Mar 11投稿 Mar 12 with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Fri Mar 12 16:08:06 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519810, encodeId=6e58519810e6, content=投稿命中率:25.0 经验分享：meta分析，八天到编辑手里，两天后被拒，说不适合他们的读者群体。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=428, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160302/IMG56D6C38ABA3084997.jpg, createdBy=62fd1694347, createdName=旭哥, createdTime=Thu Mar 03 09:04:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800825, encodeId=a45a800825de, content=请问该期刊With Editor一般多久，该状态主要干什么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Jul 01 21:24:06 CST 2020, time=2020-07-01, status=1, ipAttribution=)]

2022-09-12 ms3000000995770335

审稿速度:2.0
偏重的研究方向：乳腺癌;人工智能;病理组学
经验分享：九月二号投稿，九月五号直接跳过了with editor直接进入under review，九月八号两个审稿人接受审稿，目前任然这种状态

157 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2261187, encodeId=ca36226118e75, content=第一次投稿3天就拒了，理由是英语不行。隔了几天送公司润色以后重投，2周了还在with editor，什么情况呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f03a5212947, createdName=147637f2m97(暂无昵称), createdTime=Sat Apr 19 21:34:33 CST 2025, time=2025-04-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2121386, encodeId=d1be212138615, content=偏重的研究方向：乳腺癌 经验分享：3月15号投稿，with editor一个星期了还没变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=693f2340343, createdName=1228cbd9m21暂无昵称, createdTime=Thu Mar 23 18:13:28 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248480, encodeId=264a124848078, content=偏重的研究方向：乳腺癌;人工智能;病理组学 经验分享：九月二号投稿，九月五号under review，九月八号两个审稿人审稿，目前还没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:24:24 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248479, encodeId=dff212484e9fb, content=审稿速度:2.0 偏重的研究方向：乳腺癌;人工智能;病理组学 经验分享：九月二号投稿，九月五号直接跳过了with editor直接进入under review，九月八号两个审稿人接受审稿，目前任然这种状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:13:04 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236987, encodeId=0c74123698e5b, content=偏重的研究方向：临床试验 经验分享：2022-8-5投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3998253073, createdName=ms8000002072646838, createdTime=Sat Aug 06 20:56:00 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215107, encodeId=e8f4121510ec2, content=投稿命中率:50.0 经验分享：刚才写错了，应该是with editor要整整28天，然后才决定是送审还是直接拒稿。一审时间用21天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:29:02 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215106, encodeId=20aa12151064f, content=投稿命中率:50.0 经验分享：一审时间28天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:25:48 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947694, encodeId=42fb94e6942d, content=Mar 11投稿 Mar 12 with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Fri Mar 12 16:08:06 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519810, encodeId=6e58519810e6, content=投稿命中率:25.0 经验分享：meta分析，八天到编辑手里，两天后被拒，说不适合他们的读者群体。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=428, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160302/IMG56D6C38ABA3084997.jpg, createdBy=62fd1694347, createdName=旭哥, createdTime=Thu Mar 03 09:04:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800825, encodeId=a45a800825de, content=请问该期刊With Editor一般多久，该状态主要干什么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Jul 01 21:24:06 CST 2020, time=2020-07-01, status=1, ipAttribution=)]

2022-08-06 ms8000002072646838

偏重的研究方向：临床试验
经验分享：2022-8-5投稿

165 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2261187, encodeId=ca36226118e75, content=第一次投稿3天就拒了，理由是英语不行。隔了几天送公司润色以后重投，2周了还在with editor，什么情况呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f03a5212947, createdName=147637f2m97(暂无昵称), createdTime=Sat Apr 19 21:34:33 CST 2025, time=2025-04-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2121386, encodeId=d1be212138615, content=偏重的研究方向：乳腺癌 经验分享：3月15号投稿，with editor一个星期了还没变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=693f2340343, createdName=1228cbd9m21暂无昵称, createdTime=Thu Mar 23 18:13:28 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248480, encodeId=264a124848078, content=偏重的研究方向：乳腺癌;人工智能;病理组学 经验分享：九月二号投稿，九月五号under review，九月八号两个审稿人审稿，目前还没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:24:24 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248479, encodeId=dff212484e9fb, content=审稿速度:2.0 偏重的研究方向：乳腺癌;人工智能;病理组学 经验分享：九月二号投稿，九月五号直接跳过了with editor直接进入under review，九月八号两个审稿人接受审稿，目前任然这种状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:13:04 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236987, encodeId=0c74123698e5b, content=偏重的研究方向：临床试验 经验分享：2022-8-5投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3998253073, createdName=ms8000002072646838, createdTime=Sat Aug 06 20:56:00 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215107, encodeId=e8f4121510ec2, content=投稿命中率:50.0 经验分享：刚才写错了，应该是with editor要整整28天，然后才决定是送审还是直接拒稿。一审时间用21天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:29:02 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215106, encodeId=20aa12151064f, content=投稿命中率:50.0 经验分享：一审时间28天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:25:48 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947694, encodeId=42fb94e6942d, content=Mar 11投稿 Mar 12 with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Fri Mar 12 16:08:06 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519810, encodeId=6e58519810e6, content=投稿命中率:25.0 经验分享：meta分析，八天到编辑手里，两天后被拒，说不适合他们的读者群体。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=428, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160302/IMG56D6C38ABA3084997.jpg, createdBy=62fd1694347, createdName=旭哥, createdTime=Thu Mar 03 09:04:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800825, encodeId=a45a800825de, content=请问该期刊With Editor一般多久，该状态主要干什么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Jul 01 21:24:06 CST 2020, time=2020-07-01, status=1, ipAttribution=)]

2022-04-27 cindyspinach

投稿命中率:50.0
经验分享：刚才写错了，应该是with editor要整整28天，然后才决定是送审还是直接拒稿。一审时间用21天。

177 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2261187, encodeId=ca36226118e75, content=第一次投稿3天就拒了，理由是英语不行。隔了几天送公司润色以后重投，2周了还在with editor，什么情况呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f03a5212947, createdName=147637f2m97(暂无昵称), createdTime=Sat Apr 19 21:34:33 CST 2025, time=2025-04-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2121386, encodeId=d1be212138615, content=偏重的研究方向：乳腺癌 经验分享：3月15号投稿，with editor一个星期了还没变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=693f2340343, createdName=1228cbd9m21暂无昵称, createdTime=Thu Mar 23 18:13:28 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248480, encodeId=264a124848078, content=偏重的研究方向：乳腺癌;人工智能;病理组学 经验分享：九月二号投稿，九月五号under review，九月八号两个审稿人审稿，目前还没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:24:24 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248479, encodeId=dff212484e9fb, content=审稿速度:2.0 偏重的研究方向：乳腺癌;人工智能;病理组学 经验分享：九月二号投稿，九月五号直接跳过了with editor直接进入under review，九月八号两个审稿人接受审稿，目前任然这种状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:13:04 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236987, encodeId=0c74123698e5b, content=偏重的研究方向：临床试验 经验分享：2022-8-5投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3998253073, createdName=ms8000002072646838, createdTime=Sat Aug 06 20:56:00 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215107, encodeId=e8f4121510ec2, content=投稿命中率:50.0 经验分享：刚才写错了，应该是with editor要整整28天，然后才决定是送审还是直接拒稿。一审时间用21天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:29:02 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215106, encodeId=20aa12151064f, content=投稿命中率:50.0 经验分享：一审时间28天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:25:48 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947694, encodeId=42fb94e6942d, content=Mar 11投稿 Mar 12 with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Fri Mar 12 16:08:06 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519810, encodeId=6e58519810e6, content=投稿命中率:25.0 经验分享：meta分析，八天到编辑手里，两天后被拒，说不适合他们的读者群体。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=428, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160302/IMG56D6C38ABA3084997.jpg, createdBy=62fd1694347, createdName=旭哥, createdTime=Thu Mar 03 09:04:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800825, encodeId=a45a800825de, content=请问该期刊With Editor一般多久，该状态主要干什么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Jul 01 21:24:06 CST 2020, time=2020-07-01, status=1, ipAttribution=)]

2022-04-27 cindyspinach

投稿命中率:50.0
经验分享：一审时间28天

167 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2261187, encodeId=ca36226118e75, content=第一次投稿3天就拒了，理由是英语不行。隔了几天送公司润色以后重投，2周了还在with editor，什么情况呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f03a5212947, createdName=147637f2m97(暂无昵称), createdTime=Sat Apr 19 21:34:33 CST 2025, time=2025-04-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2121386, encodeId=d1be212138615, content=偏重的研究方向：乳腺癌 经验分享：3月15号投稿，with editor一个星期了还没变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=693f2340343, createdName=1228cbd9m21暂无昵称, createdTime=Thu Mar 23 18:13:28 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248480, encodeId=264a124848078, content=偏重的研究方向：乳腺癌;人工智能;病理组学 经验分享：九月二号投稿，九月五号under review，九月八号两个审稿人审稿，目前还没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:24:24 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248479, encodeId=dff212484e9fb, content=审稿速度:2.0 偏重的研究方向：乳腺癌;人工智能;病理组学 经验分享：九月二号投稿，九月五号直接跳过了with editor直接进入under review，九月八号两个审稿人接受审稿，目前任然这种状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:13:04 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236987, encodeId=0c74123698e5b, content=偏重的研究方向：临床试验 经验分享：2022-8-5投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3998253073, createdName=ms8000002072646838, createdTime=Sat Aug 06 20:56:00 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215107, encodeId=e8f4121510ec2, content=投稿命中率:50.0 经验分享：刚才写错了，应该是with editor要整整28天，然后才决定是送审还是直接拒稿。一审时间用21天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:29:02 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215106, encodeId=20aa12151064f, content=投稿命中率:50.0 经验分享：一审时间28天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:25:48 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947694, encodeId=42fb94e6942d, content=Mar 11投稿 Mar 12 with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Fri Mar 12 16:08:06 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519810, encodeId=6e58519810e6, content=投稿命中率:25.0 经验分享：meta分析，八天到编辑手里，两天后被拒，说不适合他们的读者群体。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=428, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160302/IMG56D6C38ABA3084997.jpg, createdBy=62fd1694347, createdName=旭哥, createdTime=Thu Mar 03 09:04:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800825, encodeId=a45a800825de, content=请问该期刊With Editor一般多久，该状态主要干什么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Jul 01 21:24:06 CST 2020, time=2020-07-01, status=1, ipAttribution=)]

2021-03-12 1465389cm38暂无昵称

Mar 11投稿 Mar 12 with editor

211 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2261187, encodeId=ca36226118e75, content=第一次投稿3天就拒了，理由是英语不行。隔了几天送公司润色以后重投，2周了还在with editor，什么情况呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f03a5212947, createdName=147637f2m97(暂无昵称), createdTime=Sat Apr 19 21:34:33 CST 2025, time=2025-04-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2121386, encodeId=d1be212138615, content=偏重的研究方向：乳腺癌 经验分享：3月15号投稿，with editor一个星期了还没变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=693f2340343, createdName=1228cbd9m21暂无昵称, createdTime=Thu Mar 23 18:13:28 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248480, encodeId=264a124848078, content=偏重的研究方向：乳腺癌;人工智能;病理组学 经验分享：九月二号投稿，九月五号under review，九月八号两个审稿人审稿，目前还没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:24:24 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248479, encodeId=dff212484e9fb, content=审稿速度:2.0 偏重的研究方向：乳腺癌;人工智能;病理组学 经验分享：九月二号投稿，九月五号直接跳过了with editor直接进入under review，九月八号两个审稿人接受审稿，目前任然这种状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:13:04 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236987, encodeId=0c74123698e5b, content=偏重的研究方向：临床试验 经验分享：2022-8-5投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3998253073, createdName=ms8000002072646838, createdTime=Sat Aug 06 20:56:00 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215107, encodeId=e8f4121510ec2, content=投稿命中率:50.0 经验分享：刚才写错了，应该是with editor要整整28天，然后才决定是送审还是直接拒稿。一审时间用21天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:29:02 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215106, encodeId=20aa12151064f, content=投稿命中率:50.0 经验分享：一审时间28天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:25:48 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947694, encodeId=42fb94e6942d, content=Mar 11投稿 Mar 12 with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Fri Mar 12 16:08:06 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519810, encodeId=6e58519810e6, content=投稿命中率:25.0 经验分享：meta分析，八天到编辑手里，两天后被拒，说不适合他们的读者群体。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=428, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160302/IMG56D6C38ABA3084997.jpg, createdBy=62fd1694347, createdName=旭哥, createdTime=Thu Mar 03 09:04:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800825, encodeId=a45a800825de, content=请问该期刊With Editor一般多久，该状态主要干什么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Jul 01 21:24:06 CST 2020, time=2020-07-01, status=1, ipAttribution=)]

2016-03-03 旭哥

投稿命中率:25.0
经验分享：meta分析，八天到编辑手里，两天后被拒，说不适合他们的读者群体。

428 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2261187, encodeId=ca36226118e75, content=第一次投稿3天就拒了，理由是英语不行。隔了几天送公司润色以后重投，2周了还在with editor，什么情况呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f03a5212947, createdName=147637f2m97(暂无昵称), createdTime=Sat Apr 19 21:34:33 CST 2025, time=2025-04-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2121386, encodeId=d1be212138615, content=偏重的研究方向：乳腺癌 经验分享：3月15号投稿，with editor一个星期了还没变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=693f2340343, createdName=1228cbd9m21暂无昵称, createdTime=Thu Mar 23 18:13:28 CST 2023, time=2023-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248480, encodeId=264a124848078, content=偏重的研究方向：乳腺癌;人工智能;病理组学 经验分享：九月二号投稿，九月五号under review，九月八号两个审稿人审稿，目前还没有变化, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:24:24 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248479, encodeId=dff212484e9fb, content=审稿速度:2.0 偏重的研究方向：乳腺癌;人工智能;病理组学 经验分享：九月二号投稿，九月五号直接跳过了with editor直接进入under review，九月八号两个审稿人接受审稿，目前任然这种状态, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230326/4f513275f85942e79c2aee2c7fa51855/91079839e40b4a49bc084a8ec14053b3.jpg, createdBy=35095644735, createdName=ms3000000995770335, createdTime=Mon Sep 12 10:13:04 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236987, encodeId=0c74123698e5b, content=偏重的研究方向：临床试验 经验分享：2022-8-5投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3998253073, createdName=ms8000002072646838, createdTime=Sat Aug 06 20:56:00 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215107, encodeId=e8f4121510ec2, content=投稿命中率:50.0 经验分享：刚才写错了，应该是with editor要整整28天，然后才决定是送审还是直接拒稿。一审时间用21天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:29:02 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215106, encodeId=20aa12151064f, content=投稿命中率:50.0 经验分享：一审时间28天, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5dbd1694143, createdName=cindyspinach, createdTime=Wed Apr 27 20:25:48 CST 2022, time=2022-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947694, encodeId=42fb94e6942d, content=Mar 11投稿 Mar 12 with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=211, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=969f5129926, createdName=1465389cm38暂无昵称, createdTime=Fri Mar 12 16:08:06 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=519810, encodeId=6e58519810e6, content=投稿命中率:25.0 经验分享：meta分析，八天到编辑手里，两天后被拒，说不适合他们的读者群体。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=428, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160302/IMG56D6C38ABA3084997.jpg, createdBy=62fd1694347, createdName=旭哥, createdTime=Thu Mar 03 09:04:00 CST 2016, time=2016-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800825, encodeId=a45a800825de, content=请问该期刊With Editor一般多久，该状态主要干什么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231127/b4f0d751268e44e3a8cb4f42e09324f5/2450ad5bc2e449b79c8da57d5f6d1ac1.jpg, createdBy=66d25241559, createdName=147c079dm30(暂无昵称), createdTime=Wed Jul 01 21:24:06 CST 2020, time=2020-07-01, status=1, ipAttribution=)]

2020-07-01 147c079dm30(暂无昵称)

请问该期刊With Editor一般多久，该状态主要干什么

231 1 举报

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务